Poster
Quizartinib
ACoP16 | October 18-21, 2025
Hematology
Exposure-overall survival analysis for quizartinib in newly diagnosed patients with FMS-like tyrosine kinase 3-internal-tandem-duplication-positive acute myeloid leukemia
Giovanni Smania
Poster
Quizartinib
ACCP 2025 | September 14-16, 2025
Hematology
Impact of concomitant metamizole on quizartinib exposure in QuANTUM-First study
Kyoin Koo
Poster
Quizartinib
ACoP16 | October 18-21, 2025
Hematology
Physiologically based pharmacokinetic modeling of quizartinib to assess drug-drug interaction as an inhibitor of breast cancer resistance protein
Akiko Watanabe
Oral
Quizartinib
ASCO 2026 | May 29 - June 2, 2026
Hematology
Quizartinib in combination with decitabine and venetoclax in FLT3-ITD mutated AML
Musa Yilmaz
Mini-Oral
Quizartinib
EHA 2025 | June 12-15, 2025
Hematology
The combination of an FLT3-ITD, NPM1mut, and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial
Mark J. Levis